pmc logo image
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
Mads Hald Andersen, Rikke B Soerensen, Jürgen C Becker, Per thor Straten
J Transl Med. 2006; 4: 38. Published online 2006 September 4. doi: 10.1186/1479-5876-4-38
PMCID:
PMC1564416
Abstract Full Text PDF–292K
 Is Cited by the Following 3 Articles in this Archive:
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients
Jun-ichi Kobayashi, Toshihiko Torigoe, Yoshihiko Hirohashi, Satomi Idenoue, Akihiro Miyazaki, Akira Yamaguchi, Hiroyoshi Hiratsuka, Noriyuki Sato
J Transl Med. 2009; 7: 1. Published online 2009 January 6. doi: 10.1186/1479-5876-7-1
PMCID:
PMC2627828
Abstract Full Text PDF–616K
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Tetsuhiro Tsuruma, Yuji Iwayama, Tosei Ohmura, Tadashi Katsuramaki, Fumitake Hata, Tomohisa Furuhata, Koji Yamaguchi, Yasutoshi Kimura, Toshihiko Torigoe, Nobuhiko Toyota, Atsuhito Yagihashi, Yoshihiko Hirohashi, Hiroko Asanuma, Kumiko Shimozawa, Minoru Okazaki, Yasuhiro Mizushima, Naohiro Nomura, Noriyuki Sato, Koichi Hirata
J Transl Med. 2008; 6: 24. Published online 2008 May 10. doi: 10.1186/1479-5876-6-24
PMCID:
PMC2430193
Abstract Full Text PDF–336K Supplementary Material
Cancer treatment: the combination of vaccination with other therapies
Mads Hald Andersen, Rikke Bæk Sørensen, David Schrama, Inge Marie Svane, Jürgen C. Becker, Per thor Straten
Cancer Immunol Immunother. 2008 November; 57(11): 1735–1743. Published online 2008 February 20. doi: 10.1007/s00262-008-0480-y
PMCID:
PMC2522294
Abstract Full Text PDF–358K
You are here: NCBI > Literature > PubMed Central
Write to the Help Desk